# US 2021/0341378 A1 · High-content imaging of microfluidic devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341378 A1
- Document ID: US20210341378A1
- Status: Published application
- Kind: A1
- Application number: 17/375,237
- Filed: 2021-07-14
- Published: 2021-11-04
- Earliest claimed: 2019-01-22
- Assignees: Emulate, Inc.
- Applicants: EMULATE, Inc.
- Inventors: Kyung-Jin Jang; Daniel Levner; Konstantia-Roumvini Kodella; Jonathan Rubins; Debora Barreiros Petropolis; Samatha Peel; Adam M. Corrigan; Beate Ehrardt; Pedro Pinto; Dominic Williams; Matt Boeckeler; Alison J. Foster; Geraldine Hamilton; Lorna Ewart Ewart
- Web page: https://patentgrep.com/patent/US20210341378A1

## CPC

- G01N 15/1434: Optical arrangements
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- G01N 15/0227: using imaging; using holography
- G01N 15/1433: using image recognition
- G01N 15/1484: {microstructural devices}
- G01N 33/5044: {involving specific cell types}
- G01N 33/5067: {Liver cells}
- G02B 21/0072: {details concerning resolution or correction, including general design of CSOM objectives}
- G02B 21/008: {Details of detection or image processing, including general computer control}
- G06V 20/693: {Acquisition}
- G01N 15/01: specially adapted for biological cells, e.g. blood cells (investigating sedimentation of particle suspensions in blood G01N15/05)
- G01N 2015/1006: {for cytology}
- G01N 2015/144: {Imaging characterised by its optical setup}
- G01N 2015/1493: {Particle size}
- G01N 2015/1497: {Particle shape}
- G02B 21/24: Base structure
- G02B 21/34: Microscope slides, e.g. mounting specimens on microscope slides
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G02B: OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G06V: IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING

## Abstract

The present invention is related to high-content microscopy imaging of microfluidic cell culture systems. A method of high-content microfluidic device microscopy is contemplated. along with related statistical analysis and microfluidic device adaptors.

## Claims

### Claim 1

A method of imaging microfluidic devices comprising:
(a) providing a microfluidic device comprising a porous membrane, said porous membrane separating a first microfluidic channel having an endothelial cell layer and a second microfluidic channel having a second cell layer;
(b) providing a microscope capable of image acquisition;
(c) taking a first set of microscopic image acquisitions;
(d) determining a focal height and locating a standard coordinate system from said first set of microscopic image acquisitions, wherein the coordinate system is located based on the location of the membrane within the microfluidic device; and
(e) taking a second set of microscopic image acquisitions based on the coordinate system located in the first set of microscopic acquisitions;
wherein said second set of microscopic image acquisitions comprise said endothelial cell layer and said second cell layer together, separated by the membrane.

### Claim 2 (depends on 1)

The method of claim 1, wherein the microscope is a confocal microscope.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first set of microscopic acquisitions are low-resolution.

### Claim 4 (depends on 1)

The method of claim 1, wherein the second set of microscopic acquisitions are high-resolution.

### Claim 5

(canceled)

### Claim 6 (depends on 4)

The method of claim 4, wherein the second set of microscope acquisitions are used to evaluate the effect of an agent on the cells.

### Claim 7 (depends on 6)

The method of claim 6, wherein the agent is a pharmaceutical.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cells are cultured for more than seven days.

### Claim 9

(canceled)

### Claim 10 (depends on 4)

The method of claim 4, wherein the second set of microscopic acquisitions comprises a three-dimensional acquisition.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the second cell layer comprises liver cells.

### Claim 13 (depends on 12)

The method of claim 12, wherein the liver cells are hepatocytes.

### Claim 14 (depends on 13)

The method of claim 13, wherein the hepatocytes are human hepatocytes.

### Claim 15 (depends on 1)

The method of claim 1, wherein the second cell layer comprises kidney cells.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1, further comprising applying flow to the channels.

### Claim 19 (depends on 1)

The method of claim 1, wherein the second set of acquisitions, guided by the coordinate system, comprises Z stack slices through different layers of the microfluidic device.

### Claim at position 20

20-37. (canceled)

### Claim 38

A method of imaging microfluidic devices comprising:
(a) providing a microfluidic device comprising a membrane having pores, said membrane separating two microfluidic channels;
(b) providing a microscope capable of image acquisition;
(c) taking a set of low resolution microscopic image acquisitions;
(d) locating a standard coordinate system using said set of low resolution image acquisitions, wherein the coordinate system is located based on the location of said pores; and
(e) taking a set of high resolution microscopic acquisitions based on the coordinate system located in the first set of microscopic acquisitions.

### Claim at position 22

39-61. (canceled)

### Claim 62 (depends on 38)

The method of claim 38, wherein the microfluidic device is seeded with cells.

### Claim 63 (depends on 62)

The method of claim 62, wherein the high resolution set of microscopic image acquisitions is used to evaluate the effect of an agent on the cells.

### Claim at position 25

64-68. (canceled)

### Claim 69 (depends on 62)

The method of claim 62, wherein the cells are liver cells.

### Claim 70 (depends on 69)

The method of claim 69, wherein the liver cells are hepatocytes and sinusoidal endothelial cells.

### Claim 71

(canceled)

### Claim 72 (depends on 62)

The method of claim 62, wherein the cells are kidney cells.

### Claim 73 (depends on 62)

The method of claim 62, wherein the microscopic acquisitions are of individual cells.

### Claim 74

(canceled)

### Claim 75 (depends on 62)

The method of claim 62, further comprising applying flow to the channels.

### Claim 76 (depends on 75)

The method of claim 75, where in the flow exerts shear stress on the cells.

### Claim 77

A method of analyzing cellular phenotype changes following agent exposure comprising:
(a) providing a plurality of microfluidic devices comprising cells in microchannels, said microchannels comprising microchannel walls;
(b) providing a microscope capable of image acquisition;
(c) treating a number of said microfluidic devices with an agent and a number of said microfluidic devices with a control media;
(d) taking a first set of microscopic acquisitions;
(e) locating a standard coordinate system using the first set of microscope acquisitions, wherein the coordinate system is located based on the location of the microchannel walls within the microfluidic device;
(f) taking a second set of microscopic acquisitions based on the coordinate system located in the first set of microscopic acquisitions;
(g) making endpoint measurements of the acquisitions;
(h) fitting a regression model to the measurements;
(i) estimating a field effect based on the regression; and
(j) comparing the field effect from microfluidic devices treated with an agent verses microfluidic device treated with a control media;
wherein said high resolution microscopic acquisition comprises a three-dimensional microscopic acquisition.

### Claim 78 (depends on 77)

The method of claim 77, wherein said regression model is a Bayesian linear regression model.

### Claim 79 (depends on 77)

The method of claim 77, wherein said field effect is a linear field effect.

### Claim 80 (depends on 77)

The method of claim 77, wherein the microscope is a confocal microscope.

### Claim 81 (depends on 77)

The method of claim 77, wherein the first set of microscopic acquisitions are low-resolution.

### Claim 82 (depends on 77)

The method of claim 77, wherein the second set of microscopic acquisitions are high-resolution.

### Claim 83 (depends on 77)

The method of claim 77, wherein the agent is a pharmaceutical.

### Claim at position 41

84-85. (canceled)

### Claim 86 (depends on 77)

The method of claim 77, wherein the three-dimensional acquisition comprises an endothelial cell layer and hepatocyte cell layer together, separated by the membrane.

### Claim 87 (depends on 77)

The method of claim 77, wherein the cells are liver cells.

### Claim 88 (depends on 87)

The method of claim 87, wherein the liver cells are hepatocytes and sinusoidal endothelial cells.

### Claim 89 (depends on 88)

The method of claim 88, wherein the hepatocytes and sinusoidal endothelial cells are human hepatocytes and human sinusoidal endothelial cells.

### Claim 90 (depends on 77)

The method of claim 77, wherein the cells are kidney cells.

### Claim 91 (depends on 77)

The method of claim 77, wherein the microscopic acquisitions are of individual cells.

### Claim 92 (depends on 77)

The method of claim 77, further comprising applying flow to the channels.

### Claim at position 49

98-110. (canceled)
